LGALS3 and Huntington disease: These findings suggest that Gal3 may be a novel target for the treatment of HD by inhibiting neuroinflammation, reducing mHTT aggregation, attenuating motor dysfunction, and improving survival in HD mice (Siew et al., 2019).